$LEXX
Lexaria Bioscience Corp.

2025 Q1 Form 10-Q Financial Statement

#000164033425000058 Filed on January 10, 2025

View on sec.gov

Income Statement

Concept 2025 Q1 2024 Q4 2024 Q3
Revenue $183.9K
YoY Change 21.58%
Cost Of Revenue $2.720K
YoY Change -43.59%
Gross Profit $181.2K
YoY Change 23.73%
Gross Profit Margin 98.52%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $1.953M
YoY Change 239.99%
% of Gross Profit 1077.92%
Depreciation & Amortization $8.734K
YoY Change -69.65%
% of Gross Profit 4.82%
Operating Expenses $2.872M
YoY Change 123.39%
Operating Profit -$2.691M
YoY Change 136.2%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$15.92K
YoY Change -65.31%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$2.704M
YoY Change 129.26%
Net Earnings / Revenue -1470.02%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.16
COMMON SHARES
Basic Shares Outstanding 17.55M shares 17.45M shares 15.81M shares
Diluted Shares Outstanding 16.67M shares

Balance Sheet

Concept 2025 Q1 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.556M
YoY Change 379.87%
Cash & Equivalents $8.078M $6.500M
Short-Term Investments $55.81K
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $263.5K $154.5K
Other Receivables
Total Short-Term Assets $8.826M $7.898M
YoY Change 227.65% 259.04%
LONG-TERM ASSETS
Property, Plant & Equipment $270.6K $254.7K
YoY Change 15.83% 0.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $968.0K $969.8K
YoY Change 3.74% 9.68%
TOTAL ASSETS
Total Short-Term Assets $8.826M $7.898M
Total Long-Term Assets $968.0K $969.8K
Total Assets $9.794M $8.868M
YoY Change 170.04% 187.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $297.8K $1.099M
YoY Change 139.15% 310.64%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $297.8K $1.099M
Total Long-Term Liabilities
Total Liabilities $399.7K $1.209M
YoY Change 57.34% 199.26%
SHAREHOLDERS EQUITY
Retained Earnings -$54.26M -$51.56M
YoY Change 15.59% 12.66%
Common Stock $17.45K $15.81K
YoY Change 69.27% 95.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.774M $8.036M
YoY Change
Total Liabilities & Shareholders Equity $9.794M $8.868M
YoY Change 170.04% 187.54%

Cashflow Statement

Concept 2025 Q1 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$2.704M
YoY Change 129.26%
Depreciation, Depletion And Amortization $8.734K
YoY Change -69.65%
Cash From Operating Activities -$2.726M
YoY Change 130.7%
INVESTING ACTIVITIES
Capital Expenditures $24.65K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$37.80K
YoY Change -5.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $4.345M
YoY Change 138.84%
NET CHANGE
Cash From Operating Activities -$2.726M
Cash From Investing Activities -$37.80K
Cash From Financing Activities $4.345M
Net Change In Cash $1.578M
YoY Change 162.16%
FREE CASH FLOW
Cash From Operating Activities -$2.726M
Capital Expenditures $24.65K
Free Cash Flow -$2.751M
YoY Change 132.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001348362
CY2024Q4 dei Amendment Flag
AmendmentFlag
false
CY2024Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--08-31
CY2024Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000 shares
CY2024Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17452594 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15810205 shares
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2421983 shares
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4520483 shares
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2447275 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4520483 shares
CY2024Q4 dei Document Type
DocumentType
10-Q
CY2024Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q4 dei Document Period End Date
DocumentPeriodEndDate
2024-11-30
CY2024Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q4 dei Entity File Number
EntityFileNumber
000-39874
CY2024Q4 dei Entity Registrant Name
EntityRegistrantName
LEXARIA BIOSCIENCE CORP.
CY2024Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2024Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-2000871
CY2024Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
#100 – 740 McCurdy Road
CY2024Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
Kelowna
CY2024Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
BC
CY2024Q4 dei Entity Address Country
EntityAddressCountry
CA
CY2024Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
V1X 2P7
CY2024Q4 dei City Area Code
CityAreaCode
1.250
CY2024Q4 dei Local Phone Number
LocalPhoneNumber
765.6424
CY2024Q4 dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.001
CY2024Q4 dei Trading Symbol
TradingSymbol
LEXX
CY2024Q4 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q4 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q4 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q4 dei Entity Shell Company
EntityShellCompany
false
CY2025Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17552594 shares
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8078254 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6499885 usd
CY2024Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
39875 usd
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
55807 usd
CY2024Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
263491 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
154477 usd
CY2024Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
444121 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1187817 usd
CY2024Q4 us-gaap Assets Current
AssetsCurrent
8825741 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
7897986 usd
CY2024Q4 us-gaap Long Term Investments And Receivables Net
LongTermInvestmentsAndReceivablesNet
64014 usd
CY2024Q3 us-gaap Long Term Investments And Receivables Net
LongTermInvestmentsAndReceivablesNet
63575 usd
CY2024Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
128025 usd
CY2024Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
134843 usd
CY2024Q4 us-gaap Other Indefinite Lived Intangible Assets
OtherIndefiniteLivedIntangibleAssets
505373 usd
CY2024Q3 us-gaap Other Indefinite Lived Intangible Assets
OtherIndefiniteLivedIntangibleAssets
516676 usd
CY2024Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
270621 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
254709 usd
CY2024Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
968033 usd
CY2024Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
969803 usd
CY2024Q4 us-gaap Assets
Assets
9793774 usd
CY2024Q3 us-gaap Assets
Assets
8867789 usd
CY2024Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
268986 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1066409 usd
CY2024Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 usd
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4963 usd
CY2024Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
28812 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
28047 usd
CY2024Q4 us-gaap Liabilities Current
LiabilitiesCurrent
297798 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1099419 usd
CY2024Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
101920 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
109319 usd
CY2024Q4 us-gaap Liabilities
Liabilities
399718 usd
CY2024Q3 us-gaap Liabilities
Liabilities
1208738 usd
CY2024Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000 shares
CY2024Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17452594 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15810205 shares
CY2024Q4 us-gaap Common Stock Value
CommonStockValue
17453 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
15810 usd
CY2024Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
64042343 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
59599178 usd
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54262471 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-51558772 usd
CY2024Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-22991 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-19816 usd
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
9774334 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
8036400 usd
CY2024Q4 us-gaap Minority Interest
MinorityInterest
-380278 usd
CY2024Q3 us-gaap Minority Interest
MinorityInterest
-377349 usd
CY2024Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9394056 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7659051 usd
CY2024Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9793774 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8867789 usd
CY2024Q4 us-gaap Revenues
Revenues
183923 usd
CY2023Q4 us-gaap Revenues
Revenues
151278 usd
CY2024Q4 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2720 usd
CY2023Q4 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4822 usd
CY2024Q4 us-gaap Gross Profit
GrossProfit
181203 usd
CY2023Q4 us-gaap Gross Profit
GrossProfit
146456 usd
CY2024Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1953220 usd
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
574491 usd
CY2024Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
918690 usd
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
711107 usd
CY2024Q4 us-gaap Operating Expenses
OperatingExpenses
2871910 usd
CY2023Q4 us-gaap Operating Expenses
OperatingExpenses
1285598 usd
CY2024Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-2690707 usd
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1139142 usd
CY2024Q4 us-gaap Interest Income Other
InterestIncomeOther
11 usd
CY2023Q4 us-gaap Interest Income Other
InterestIncomeOther
7319 usd
CY2024Q4 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-15932 usd
CY2023Q4 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-53215 usd
CY2024Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15921 usd
CY2023Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-45896 usd
CY2024Q4 us-gaap Profit Loss
ProfitLoss
-2706628 usd
CY2023Q4 us-gaap Profit Loss
ProfitLoss
-1185038 usd
CY2024Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2929 usd
CY2023Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-5715 usd
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-2703699 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-1179323 usd
CY2024Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-3175 usd
CY2023Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
4372 usd
CY2024Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2706874 usd
CY2023Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1174951 usd
CY2024Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2024Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16668513 shares
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9051531 shares
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7659051 usd
CY2024Q4 lxrp Stock Issued In Equity Offering Amount
StockIssuedInEquityOfferingAmount
4345393 usd
CY2024Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3175 usd
CY2024Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
99415 usd
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-2703699 usd
CY2024Q4 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-2929 usd
CY2024Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9394056 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2680078 usd
CY2023Q4 lxrp Stock Issued In Equity Offering Amount
StockIssuedInEquityOfferingAmount
1247718 usd
CY2023Q4 lxrp Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
571651 usd
CY2023Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
4372 usd
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
53953 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-1179323 usd
CY2023Q4 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-5715 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3372734 usd
CY2024Q4 us-gaap Profit Loss
ProfitLoss
-2706628 usd
CY2023Q4 us-gaap Profit Loss
ProfitLoss
-1185038 usd
CY2024Q4 us-gaap Share Based Compensation
ShareBasedCompensation
99415 usd
CY2023Q4 us-gaap Share Based Compensation
ShareBasedCompensation
53953 usd
CY2024Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
33195 usd
CY2023Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
28778 usd
CY2024Q4 us-gaap Other Noncash Expense
OtherNoncashExpense
6818 usd
CY2023Q4 us-gaap Other Noncash Expense
OtherNoncashExpense
10881 usd
CY2024Q4 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-15932 usd
CY2023Q4 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-53215 usd
CY2024Q4 us-gaap Accretion Expense
AccretionExpense
2451 usd
CY2023Q4 us-gaap Accretion Expense
AccretionExpense
67 usd
CY2024Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
109014 usd
CY2023Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
408045 usd
CY2024Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-743696 usd
CY2023Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-414472 usd
CY2024Q4 us-gaap Increase Decrease In Long Term Receivables Current
IncreaseDecreaseInLongTermReceivablesCurrent
439 usd
CY2024Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-797423 usd
CY2023Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-140973 usd
CY2024Q4 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-9085 usd
CY2023Q4 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-8963 usd
CY2024Q4 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4963 usd
CY2023Q4 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 usd
CY2024Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2726045 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1181653 usd
CY2024Q4 lxrp Additions To Intellectual Property
AdditionsToIntellectualProperty
13159 usd
CY2023Q4 lxrp Additions To Intellectual Property
AdditionsToIntellectualProperty
40026 usd
CY2024Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24645 usd
CY2023Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
CY2024Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-37804 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-40026 usd
CY2024Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4345393 usd
CY2023Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1247719 usd
CY2024Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
CY2023Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
571651 usd
CY2024Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4345393 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1819370 usd
CY2024Q4 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-3175 usd
CY2023Q4 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4372 usd
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1578369 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
602063 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6499885 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1352102 usd
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8078254 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1954165 usd
CY2024Q4 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023Q4 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
3662 usd
CY2024Q4 us-gaap Nature Of Operations
NatureOfOperations
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. Nature of Business</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Lexaria Bioscience Corp. (“Lexaria”, “we”, “our” or “the Company”) is a biotechnology company pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“API”) using our proprietary DehydraTECH drug delivery technology.  Our current focus is the investigation of the incorporation of our DehydraTECH drug delivery technology with GLP-1 and GIP drugs to enhance absorption and reduce adverse side effects.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Revenues are generated from licensing contracts for the Company’s patented DehydraTECH technology based on the terms of use and defined geographic and licensing arrangements. We derive income from our third party contracted manufacturing of B2B DehydraTECH enhanced products made to customer specifications that are sold online and in-store in the US and Canada. We also perform contract services in R&amp;D for customer specific formulations that are used in comparison testing to customers’ existing products. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><strong>Liquidity </strong><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and in accordance with accounting principles generally accepted in the United States (“US GAAP”) applicable to a going concern, which assumes the Company will have sufficient funds to meet its financial obligations for a period of at least 12 months from the date of this report.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Since inception, the Company has incurred significant operating and net losses. Net losses attributable to shareholders were $2.7 million and $1.2 million for the three-months ended November 30, 2024, and 2023, respectively. As of November 30, 2024, we had an accumulated deficit of $54.3 million. We expect to continue to incur significant operational expenses and net losses in the upcoming 12 months. Our net losses may fluctuate significantly from quarter to quarter and year to year, depending on the stage and complexity of our research and development (R&amp;D) studies and corporate expenditures, additional revenues received from the licensing of our technology, if any, and the receipt of payments under any current or future collaborations into which we may enter. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended November 30, 2024, we raised $4.3 million in net proceeds from the sale of securities pursuant to our registered direct and At the Market offerings which closed in October, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We may offer securities in response to market conditions or other circumstances if we believe such a plan of financing is required to advance the Company’s business plans. There is no certainty that future equity or debt financing will be available or that it will be at acceptable terms and the outcome of these matters is unpredictable. A lack of adequate funding may force us to reduce spending, curtail or suspend planned programs or possibly liquidate assets. Any of these actions could adversely and materially affect our business, cash flow, financial condition, results of operations, and potential prospects. The sale of additional equity may result in additional dilution to our stockholders. Entering into additional licensing agreements, collaborations, partnerships, alliances marketing, distribution, or licensing arrangements with third parties to increase our capital resources is also possible. If we do so, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on existing cash resources, management believes that current funding will be sufficient to meet the Company’s financial obligations for a period of at least twelve months from the date of this report.</p>
CY2024Q4 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
2700000 usd
CY2023Q4 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
1200000 usd
CY2024Q4 us-gaap Cumulative Earnings Deficit
CumulativeEarningsDeficit
-54300000 usd
CY2024Q4 us-gaap Stockholders Equity Other
StockholdersEquityOther
4300000 usd
CY2024Q4 lxrp Intellectual Property Life
IntellectualPropertyLife
P20Y
CY2024Q4 lxrp Marketable Securities Carrying Value
MarketableSecuritiesCarryingValue
39875 usd
CY2024Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
39875 usd
CY2024Q3 lxrp Marketable Securities Carrying Value
MarketableSecuritiesCarryingValue
55807 usd
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
55807 usd
CY2024Q4 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company places its cash with a high credit quality financial institution. Periodically, the Company may carry cash balances at such financial institution in excess of the federally insured limit of $250,000. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the three-months ended November 30, 2024, two customers accounted for 100% of consolidated revenues. In the three-months ended November 30, 2023, two customers accounted for 96% of consolidated revenues.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of November 30, 2024, the Company had $89,491 in sales tax receivable, as compared to $70,477 as of August 31, 2024.  The Company considers its credit risk to be low for such receivables.</p>
CY2024Q4 us-gaap Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
250000 usd
CY2024Q4 lxrp Sales Taxes Receivable
SalesTaxesReceivable
89491 usd
CY2024Q3 lxrp Sales Taxes Receivable
SalesTaxesReceivable
70477 usd
CY2024Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
327505 usd
CY2024Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
218052 usd
CY2024Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
444121 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1187817 usd
CY2024Q4 lxrp Intellectual Property Balance Beginning
IntellectualPropertyBalanceBeginning
516676 usd
CY2024 lxrp Intellectual Property Balance Beginning
IntellectualPropertyBalanceBeginning
462625 usd
CY2024Q4 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
13159 usd
CY2024 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
145591 usd
CY2024Q4 lxrp Impairment
Impairment
0 usd
CY2024 lxrp Impairment
Impairment
-57836 usd
CY2024Q4 lxrp Amortization Of Intellectual Assets
AmortizationOfIntellectualAssets
-24462 usd
CY2024 lxrp Amortization Of Intellectual Assets
AmortizationOfIntellectualAssets
-33704 usd
CY2024Q4 lxrp Intellectual Property Balance Ending
IntellectualPropertyBalanceEnding
505373 usd
CY2024 lxrp Intellectual Property Balance Ending
IntellectualPropertyBalanceEnding
516676 usd
CY2024Q4 us-gaap Exploration Expense
ExplorationExpense
24462 usd
CY2023Q4 us-gaap Exploration Expense
ExplorationExpense
8274 usd
CY2024Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
25269 usd
CY2024Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
25269 usd
CY2024Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
25269 usd
CY2024Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
25269 usd
CY2024Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
25269 usd
CY2024Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
379028 usd
CY2024Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
505373 usd
CY2024Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
772326 usd
CY2024Q4 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
24646 usd
CY2024Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
526351 usd
CY2024Q4 us-gaap Property Plant And Equipment Other Net
PropertyPlantAndEquipmentOtherNet
270621 usd
CY2024Q3 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
729311 usd
CY2024 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
43014 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
517616 usd
CY2024Q3 us-gaap Property Plant And Equipment Other Net
PropertyPlantAndEquipmentOtherNet
254709 usd
CY2024Q4 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8734 usd
CY2024 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
42448 usd
CY2024Q4 us-gaap Cost Of Goods And Services Sold Depreciation And Amortization
CostOfGoodsAndServicesSoldDepreciationAndAmortization
0 usd
CY2024 us-gaap Cost Of Goods And Services Sold Depreciation And Amortization
CostOfGoodsAndServicesSoldDepreciationAndAmortization
0 usd
CY2024Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
268986 usd
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
1066409 usd
CY2024Q4 lxrp Income From Ongoing Operations
IncomeFromOngoingOperations
183923 usd
CY2023Q4 lxrp Income From Ongoing Operations
IncomeFromOngoingOperations
151278 usd
CY2024Q4 lxrp Product Revenues
ProductRevenues
9923 usd
CY2023Q4 lxrp Product Revenues
ProductRevenues
5388 usd
CY2024Q4 lxrp Licensing Revenue
LicensingRevenue
174000 usd
CY2023Q4 lxrp Licensing Revenue
LicensingRevenue
144990 usd
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5931649 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.50
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
2977830 shares
CY2024Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.39
CY2024Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2953819 shares
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.62
CY2024Q4 lxrp Class Of Warrant Or Right Outstandings
ClassOfWarrantOrRightOutstandings
2953819 shares
CY2024Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.62
CY2024Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P1Y10M9D
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Description
ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
The Company established an Equity Incentive Plan whereby our Board, pursuant to shareholder approved amendments, may grant up to 1,745,259 stock options to directors, officers, employees, and consultants with such number being increased to up to 10% of the issued share capital at the end of each calendar year, at the discretion of the board, pursuant to an evergreen formula
CY2024Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y6M
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2024Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
99415 usd
CY2023Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
53953 usd
CY2024Q4 lxrp Right Of Use Assets Operating Leases
RightOfUseAssetsOperatingLeases
156748 usd
CY2024 lxrp Right Of Use Assets Operating Leases
RightOfUseAssetsOperatingLeases
167446 usd
CY2024Q4 lxrp Amortization Of Lease Asset
AmortizationOfLeaseAsset
-28723 usd
CY2024 lxrp Amortization Of Lease Asset
AmortizationOfLeaseAsset
-32603 usd
CY2024Q4 lxrp Lease Assets
LeaseAssets
128025 usd
CY2024 lxrp Lease Assets
LeaseAssets
134843 usd
CY2024Q4 lxrp Operating Lease Liabilities
OperatingLeaseLiabilities
156748 usd
CY2024 lxrp Operating Lease Liabilities
OperatingLeaseLiabilities
163967 usd
CY2024Q4 lxrp Lease Payments
LeasePayments
-37456 usd
CY2024 lxrp Lease Payments
LeasePayments
-33273 usd
CY2024Q4 lxrp Operatingleaseinterest Accretion
OperatingleaseinterestAccretion
11440 usd
CY2024 lxrp Operatingleaseinterest Accretion
OperatingleaseinterestAccretion
6672 usd
CY2024Q4 lxrp Lease Liabilities Operating Lease
LeaseLiabilitiesOperatingLease
130732 usd
CY2024 lxrp Lease Liabilities Operating Lease
LeaseLiabilitiesOperatingLease
137366 usd
CY2024Q4 us-gaap Operating Lease Cost
OperatingLeaseCost
128026 usd
CY2024 us-gaap Operating Lease Cost
OperatingLeaseCost
134843 usd
CY2024Q4 lxrp Operating Cash Flows For Lease Payments
OperatingCashFlowsForLeasePayments
-37456 usd
CY2024 lxrp Operating Cash Flows For Lease Payments
OperatingCashFlowsForLeasePayments
-33273 usd
CY2024Q4 lxrp Remaining Lease Term
RemainingLeaseTerm
P3Y11M15D
CY2024 lxrp Remaining Lease Term
RemainingLeaseTerm
P4Y2M15D
CY2024Q4 us-gaap Malpractice Loss Contingency Discount Rate
MalpracticeLossContingencyDiscountRate
0.0725 pure
CY2024 us-gaap Malpractice Loss Contingency Discount Rate
MalpracticeLossContingencyDiscountRate
0.0725 pure
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
0 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
28009 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
37345 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
38641 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
38901 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
8104 usd
CY2024Q4 lxrp Lessee Operating Lease Liability Payments Due Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueThereafter
0 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
151000 usd
CY2024Q4 lxrp Operating Imputed Interest
OperatingImputedInterest
-20268 usd
CY2024Q4 lxrp Present Value Of Operating Lease Liabilities
PresentValueOfOperatingLeaseLiabilities
130732 usd
CY2024Q4 lxrp Less Current Obligations Under Leases
LessCurrentObligationsUnderLeases
-28812 usd
CY2024Q4 lxrp Maturities Total Value Of Operating Lease Liability
MaturitiesTotalValueOfOperatingLeaseLiability
101920 usd
CY2024Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
183923 usd
CY2024Q4 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2720 usd
CY2024Q4 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
2871910 usd
CY2024Q4 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-15921 usd
CY2024Q4 lxrp Segment Income Loss
SegmentIncomeLoss
-2706628 usd
CY2024Q4 us-gaap Assets Net
AssetsNet
9793774 usd
CY2023Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
151278 usd
CY2023Q4 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4822 usd
CY2023Q4 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1285597 usd
CY2023Q4 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-45897 usd
CY2023Q4 lxrp Segment Income Loss
SegmentIncomeLoss
-1185038 usd
CY2023Q4 us-gaap Assets Net
AssetsNet
3626774 usd

Files In Submission

Name View Source Status
0001640334-25-000058-index-headers.html Edgar Link pending
0001640334-25-000058-index.html Edgar Link pending
0001640334-25-000058.txt Edgar Link pending
0001640334-25-000058-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
lxrp-20241130.xsd Edgar Link pending
lxrp_10q.htm Edgar Link pending
lxrp_ex104.htm Edgar Link pending
lxrp_ex104img24.jpg Edgar Link pending
lxrp_ex104img25.jpg Edgar Link pending
lxrp_ex104img26.jpg Edgar Link pending
lxrp_ex104img27.jpg Edgar Link pending
lxrp_ex104img28.jpg Edgar Link pending
lxrp_ex105.htm Edgar Link pending
lxrp_ex311.htm Edgar Link pending
lxrp_ex312.htm Edgar Link pending
lxrp_ex321.htm Edgar Link pending
lxrp_ex322.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
lxrp-20241130_pre.xml Edgar Link unprocessable
lxrp_10q_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
lxrp-20241130_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
lxrp-20241130_def.xml Edgar Link unprocessable
lxrp-20241130_lab.xml Edgar Link unprocessable